Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba
2014 (English)In: Atherosclerosis, ISSN 0021-9150, E-ISSN 1879-1484, Vol. 237, no 2, 584-588 p.Article in journal (Refereed) Published
In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85 +/- 4.09 to 4.92 +/- 2.51 mg/L (-44.4%) (p < 0.0436) and HOMA-IR from 3.07 +/- 0.63 to 2.60 +/- 0.51 mU/L x mg/dL (-15.3%) (p < 0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p < 0.0407) and nanoplaque formation (-14.3%, p < 0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.
Place, publisher, year, edition, pages
2014. Vol. 237, no 2, 584-588 p.
Metabolic syndrome patients, High-sensitivity C-reactive protein (hs-CRP), Homeostasis model assessment of insulin resistance (HOMA-IR), CVD/total mortality risk, Ginkgo biloba
Cardiac and Cardiovascular Systems
IdentifiersURN: urn:nbn:se:uu:diva-241413DOI: 10.1016/j.atherosclerosis.2014.10.023ISI: 000346066600061PubMedID: 25463092OAI: oai:DiVA.org:uu-241413DiVA: diva2:781983